FDA CBER Launches Gene Therapy Patient Listening Program to Shape Long-Term Follow-Up Registry Requirements

Post-market surveillance obligations for approved gene therapies are moving into sharper regulatory focus, as FDA's Center for Biologics Evaluation and Research (CBER) convened a formal patient and care partner listening meeting on September 20, 2024, to gather input that will directly inform long-term follow-up study design and registry protocols.

The meeting, running from 11:00 a.m. to 4:30 p.m. ET, was structured across two sessions. The first examined how patients and care partners weigh short- and long-term risks when deciding whether to accept an approved gene therapy, including scenarios where multiple treatment options exist. The second session addressed registry participation directly: what factors drive or deter enrollment, how patients expect registries to be designed and operated, and what longitudinal outcome data should be communicated back to participants.

For biologics manufacturers and QA leads, the registry design session carries the more immediate operational weight. CBER's stated objective, to develop patient-centered protocols for long-term studies capturing gene therapy outcomes, signals that agency expectations around post-approval commitments are being actively shaped by this input. Manufacturers holding approved gene therapy biologics licenses, or those advancing late-stage programs, should treat the docket record as an early indicator of where post-market surveillance guidance is heading.

A public docket, FDA-2024-N-3208, was opened concurrently on September 20, 2024, at Regulations.gov. Polling results from the meeting are available within that docket. Written and electronic comments were accepted through November 19, 2024, providing a formal channel for manufacturers and sponsors to submit perspectives on registry feasibility, patient burden, and data collection infrastructure.

The broader regulatory context is relevant here. 21 CFR Part 312 already imposes long-term follow-up requirements on gene therapy IND holders, and CBER has issued guidance on observational study design for this product class. What this listening meeting adds is a patient-experience layer that the agency has indicated will feed into protocol development, meaning future registry requirements may reflect patient-reported barriers to participation, including study duration, visit burden, and data transparency expectations.

Regulatory affairs teams monitoring CBER's biologics pipeline should track subsequent guidance documents citing docket FDA-2024-N-3208, as the agency's synthesis of patient input is expected to translate into updated post-market study recommendations for this product class.

Source: FDA CBER via What's New, Vaccines, Blood & Biologics RSS Feed, published June 11, 2026; meeting held September 20, 2024. Docket FDA-2024-N-3208 available at Regulations.gov.